ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for NTLA

Stock NameIntellia Therapeutics Inc
TickerNTLA(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS45826J1051
LEI5493002T5BCPE5DZC723

Show aggregate NTLA holdings

News associated with NTLA

Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus
Even in a choppy market, Zacks' strategies are spotlighting winners like Oracle, Intellia, and Pharming Group, proving the value of a disciplined, research-driven approach. - 2025-09-02 10:03:00
Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Up After Insider Buying Activity
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) shares gapped up before the market opened on Monday following insider buying activity. The stock had previously closed at $10.52, but opened at $11.07. Intellia Therapeutics shares last traded at $11.34, with a volume of 1,615,773 shares trading hands. Specifically, Director William J. Chase purchased 100,000 shares […] - 2025-08-27 02:18:42
Mitsubishi UFJ Asset Management Co. Ltd. Boosts Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 24.1% in the 1st quarter, HoldingsChannel reports. The firm owned 21,458 shares of the company’s stock after buying an additional 4,165 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Intellia Therapeutics were worth […] - 2025-08-15 05:44:58
Take the Zacks Approach to Beat the Markets: Digi Power X, RF Industries & Starbucks in Focus
Zacks spotlights Digi Power X, RF Industries and Starbucks as standout gainers amid market volatility and economic uncertainty. - 2025-08-11 08:43:00
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by XTX Topco Ltd
XTX Topco Ltd boosted its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 84.2% in the 1st quarter, HoldingsChannel reports. The firm owned 80,897 shares of the company’s stock after purchasing an additional 36,989 shares during the period. XTX Topco Ltd’s holdings in Intellia Therapeutics were worth $575,000 at the end of the […] - 2025-08-07 04:58:54
Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus
AU, CAT and HSY are standing out as Zacks' high-conviction picks, with each posting double-digit gains in recent weeks. - 2025-07-28 09:41:00
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Rating of “Moderate Buy” from Analysts
Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have earned an average recommendation of “Moderate Buy” from the twenty ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, twelve have given a buy rating […] - 2025-07-24 05:11:08
Commit To Buy Intellia Therapeutics At $10, Earn 28.5% Using Options
Investors considering a purchase of Intellia Therapeutics Inc (Symbol: NTLA) stock, but tentative about paying the going market price of $13.21/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in - 2025-07-21 12:36:47
Alps Advisors Inc. Sells 5,030 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Alps Advisors Inc. trimmed its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 6.1% in the 1st quarter, Holdings Channel reports. The firm owned 77,328 shares of the company’s stock after selling 5,030 shares during the quarter. Alps Advisors Inc.’s holdings in Intellia Therapeutics were worth $550,000 at the end of […] - 2025-07-15 06:25:51
Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus
Zacks' model upgrades drove major gains for Amarin, Mogo and 3M, even as broader markets wobbled on tariff fears. - 2025-07-14 10:06:00
Wealth Enhancement Advisory Services LLC Makes New Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Wealth Enhancement Advisory Services LLC purchased a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,789 shares of the company’s stock, valued at approximately $98,000. Several other large investors also recently modified […] - 2025-07-11 04:16:51
Brokerages Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target at $33.37
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) has been given an average rating of “Moderate Buy” by the twenty research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has given […] - 2025-07-02 03:14:50
SG Americas Securities LLC Sells 3,401 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
SG Americas Securities LLC lessened its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 7.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 41,437 shares of the company’s stock after selling 3,401 shares during the quarter. SG Americas Securities LLC’s […] - 2025-06-27 04:21:01
Rhumbline Advisers Reduces Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Rhumbline Advisers trimmed its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 5.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 156,838 shares of the company’s stock after selling 9,410 shares during the quarter. Rhumbline Advisers’ holdings in […] - 2025-06-20 04:22:49
GAMMA Investing LLC Raises Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
GAMMA Investing LLC increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 1,961.2% during the first quarter, Holdings Channel.com reports. The firm owned 7,544 shares of the company’s stock after acquiring an additional 7,178 shares during the quarter. GAMMA Investing LLC’s holdings in Intellia Therapeutics were worth $540,000 at the end of […] - 2025-06-19 04:08:57
Intellia Therapeutics (NASDAQ:NTLA) Earns Buy Rating from HC Wainwright
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $30.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 213.15% from the company’s current […] - 2025-06-18 02:22:53
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of “Moderate Buy” by Brokerages
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) has been given an average rating of “Moderate Buy” by the twenty-one ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, thirteen have issued a buy rating and one […] - 2025-06-04 04:52:47
Nuveen Asset Management LLC Sells 105,170 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Nuveen Asset Management LLC trimmed its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 28.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 260,697 shares of the company’s stock after selling 105,170 shares during the quarter. Nuveen Asset Management LLC’s […] - 2025-06-03 06:04:57
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 5.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 483,185 shares of the company’s […] - 2025-06-03 05:13:02
ProShare Advisors LLC Has $389,000 Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
ProShare Advisors LLC grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 38.0% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 33,404 shares of the company’s stock after acquiring an additional 9,196 shares during the period. ProShare Advisors LLC’s holdings in Intellia Therapeutics were worth $389,000 at the end […] - 2025-05-29 05:04:57
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 15,888 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 7.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 227,255 shares of the company’s stock after buying an additional 15,888 shares during the period. MIRAE […] - 2025-05-21 05:40:53
BNP Paribas Financial Markets Has $5.11 Million Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
BNP Paribas Financial Markets increased its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 78.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 438,458 shares of the company’s stock after purchasing an additional 192,096 shares during […] - 2025-05-14 06:12:50
Guggenheim Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $45.00
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target cut by investment analysts at Guggenheim from $55.00 to $45.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price target indicates a potential upside of 440.87% from the stock’s previous close. […] - 2025-05-14 02:56:48
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $36.47 Consensus Target Price from Brokerages
Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty-one research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, thirteen have assigned a buy recommendation […] - 2025-05-13 02:44:49
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Holdings Cut by Voya Investment Management LLC
Voya Investment Management LLC lessened its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 7.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 28,829 shares of the company’s stock after selling 2,213 shares during the period. Voya Investment Management LLC’s holdings in Intellia […] - 2025-05-12 05:26:58
Citigroup Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $10.00
Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its price objective reduced by Citigroup from $14.00 to $10.00 in a research note released on Friday,Benzinga reports. They currently have a neutral rating on the stock. A number of other equities analysts have also commented on the stock. Wedbush restated a “neutral” rating and issued a $10.00 […] - 2025-05-12 04:26:47
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Mariner LLC
Mariner LLC decreased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 14.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,820 shares of the company’s stock after selling 2,496 shares during the quarter. Mariner LLC’s holdings in Intellia Therapeutics were worth […] - 2025-05-08 04:38:44
Dimensional Fund Advisors LP Purchases 528,962 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Dimensional Fund Advisors LP increased its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 36.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,976,212 shares of the company’s stock after purchasing an additional 528,962 shares during the quarter. […] - 2025-05-07 05:26:54
MetLife Investment Management LLC Buys 3,491 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
MetLife Investment Management LLC boosted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 6.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 59,187 shares of the company’s stock after purchasing an additional 3,491 shares during the period. […] - 2025-05-05 05:22:56
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood's investing style is bouncing back into fancy. The co-founder, CEO, and investment manager of Ark Invest is winning again. Her most popular exchange-traded fund has risen 6% over the past month, a welcome contrast to the flat overall market in that time. Her 14% retur - 2025-04-30 11:15:00

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc NTLA holdings

DateNumber of NTLA Shares HeldBase Market Value of NTLA SharesLocal Market Value of NTLA SharesChange in NTLA Shares HeldChange in NTLA Base ValueCurrent Price per NTLA Share HeldPrevious Price per NTLA Share Held
2026-01-15 (Thursday)57,897NTLA holding increased by 8944USD 687,237NTLA holding increased by 98822USD 687,2378,944USD 98,822 USD 11.87 USD 12.02
2026-01-14 (Wednesday)48,953NTLA holding increased by 172USD 588,415NTLA holding increased by 15726USD 588,415172USD 15,726 USD 12.02 USD 11.74
2026-01-13 (Tuesday)48,781USD 572,689NTLA holding increased by 15122USD 572,6890USD 15,122 USD 11.74 USD 11.43
2026-01-12 (Monday)48,781USD 557,567NTLA holding increased by 51220USD 557,5670USD 51,220 USD 11.43 USD 10.38
2026-01-09 (Friday)48,781USD 506,347NTLA holding decreased by -6829USD 506,3470USD -6,829 USD 10.38 USD 10.52
2026-01-08 (Thursday)48,781NTLA holding increased by 172USD 513,176NTLA holding increased by 20767USD 513,176172USD 20,767 USD 10.52 USD 10.13
2026-01-07 (Wednesday)48,609USD 492,409NTLA holding increased by 19443USD 492,4090USD 19,443 USD 10.13 USD 9.73001
2026-01-06 (Tuesday)48,609USD 472,966NTLA holding increased by 17500USD 472,9660USD 17,500 USD 9.73001 USD 9.36999
2026-01-05 (Monday)48,609USD 455,466NTLA holding increased by 7777USD 455,4660USD 7,777 USD 9.36999 USD 9.21
2026-01-02 (Friday)48,609USD 447,689NTLA holding increased by 10694USD 447,6890USD 10,694 USD 9.21 USD 8.99
2025-12-31 (Wednesday)48,609USD 436,995NTLA holding decreased by -3403USD 436,9950USD -3,403 USD 8.99 USD 9.06001
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of NTLA by Blackrock for IE00B3VWM098

Show aggregate share trades of NTLA

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2026-01-15BUY8,94412.35011.340 11.441USD 102,328 11.19
2026-01-14BUY17212.34011.670 11.737USD 2,019 11.18
2026-01-08BUY17210.73710.320 10.362USD 1,782 11.19
2025-12-23SELL-1729.5509.340 9.361USD -1,610 11.26 Profit of 327 on sale
2025-12-03SELL-8609.1158.130 8.229USD -7,077 11.40 Profit of 2,724 on sale
2025-12-02BUY3448.4908.085 8.125USD 2,795 11.41
2025-11-25SELL-5168.6108.185 8.228USD -4,245 11.48 Profit of 1,679 on sale
2025-11-24SELL-5168.3708.135 8.159USD -4,210 11.50 Profit of 1,722 on sale
2025-11-17SELL-1,8928.8058.230 8.287USD -15,680 11.58 Profit of 6,223 on sale
2025-11-12SELL-17210.3309.280 9.385USD -1,614 11.62 Profit of 384 on sale
2025-11-06SELL-17213.50012.220 12.348USD -2,124 11.64 Loss of -122 on sale
2025-11-05SELL-1,72013.69012.150 12.304USD -21,163 11.63 Loss of -1,157 on sale
2025-11-04SELL-34413.11012.190 12.282USD -4,225 11.63 Loss of -225 on sale
2025-11-03SELL-34413.60012.199 12.339USD -4,245 11.62 Loss of -247 on sale
2025-10-28BUY51613.96014.790 14.707USD 7,589 11.59
2025-10-24SELL-17225.60026.350 26.275USD -4,519 11.50 Loss of -2,542 on sale
2025-10-15BUY1,03225.93026.319 26.280USD 27,121 10.93
2025-10-02BUY17220.44020.585 20.570USD 3,538 10.82
2025-09-30BUY34417.27017.530 17.504USD 6,021 10.74
2025-08-21SELL-17210.12510.245 10.233USD -1,760 10.62 Profit of 67 on sale
2025-07-31BUY51611.64012.280 12.216USD 6,303 10.62
2025-06-30SELL-3449.3809.675 9.646USD -3,318 10.48 Profit of 287 on sale
2025-06-25SELL-1729.5609.660 9.650USD -1,660 10.50 Profit of 146 on sale
2025-06-20SELL-3449.2009.943 9.869USD -3,395 10.52 Profit of 225 on sale
2025-05-30SELL-51,3606.8707.430 7.374USD -378,729 10.79 Profit of 175,357 on sale
2025-05-23BUY3499.1609.230 9.223USD 3,219 10.86
2025-05-19SELL-3499.0609.160 9.150USD -3,193 10.92 Profit of 617 on sale
2025-05-15SELL-1,0478.0758.090 8.089USD -8,469 10.96 Profit of 3,010 on sale
2025-05-12SELL-3498.5508.890 8.856USD -3,091 11.04 Profit of 761 on sale
2025-05-09SELL-3498.1208.705 8.646USD -3,018 11.06 Profit of 843 on sale
2025-04-30SELL-3498.8708.940 8.933USD -3,118 11.26 Profit of 811 on sale
2025-04-24SELL-7008.1808.230 8.225USD -5,757 11.38 Profit of 2,205 on sale
2025-04-17SELL-3507.2307.295 7.289USD -2,551 11.57 Profit of 1,498 on sale
2025-04-15SELL-1,0507.3607.760 7.720USD -8,106 11.66 Profit of 4,142 on sale
2025-04-14SELL-1,0507.5007.670 7.653USD -8,036 11.71 Profit of 4,260 on sale
2025-04-09SELL-1,4007.0807.380 7.350USD -10,290 11.87 Profit of 6,326 on sale
2025-04-07SELL-2,4506.5406.880 6.846USD -16,773 12.00 Profit of 12,615 on sale
2025-04-04SELL-3,5006.6306.910 6.882USD -24,087 12.06 Profit of 18,117 on sale
2025-03-31BUY3507.1107.830 7.758USD 2,715 12.24
2025-03-19SELL-7009.3009.389 9.380USD -6,566 12.62 Profit of 2,270 on sale
2025-03-14SELL-2,1069.1409.600 9.554USD -20,121 12.76 Profit of 6,758 on sale
2025-03-13SELL-7049.22010.180 10.084USD -7,099 12.81 Profit of 1,922 on sale
2025-03-12SELL-11,9689.6209.660 9.656USD -115,563 12.86 Profit of 38,342 on sale
2025-03-07SELL-70410.35010.680 10.647USD -7,495 13.00 Profit of 1,659 on sale
2025-03-06SELL-1,0569.90010.000 9.990USD -10,549 13.05 Profit of 3,232 on sale
2025-03-03SELL-3529.45010.369 10.277USD -3,618 13.23 Profit of 1,040 on sale
2025-02-28BUY50,37610.09010.340 10.315USD 519,628 13.28
2025-02-26SELL-21310.80011.100 11.070USD -2,358 13.37 Profit of 489 on sale
2025-02-25SELL-63910.71011.860 11.745USD -7,505 13.41 Profit of 1,066 on sale
2025-02-18BUY1,06511.53012.050 11.998USD 12,778 13.55
2025-02-13BUY2139.6409.715 9.708USD 2,068 13.74
2025-02-12BUY2139.5109.580 9.573USD 2,039 13.83
2025-02-11BUY6399.2109.476 9.449USD 6,038 13.93
2025-02-06BUY1,91710.13010.730 10.670USD 20,454 14.20
2025-01-27BUY21310.55010.774 10.752USD 2,290 15.07
2024-12-30BUY1,06311.41011.850 11.806USD 12,550 15.51
2024-12-06BUY84814.72014.880 14.864USD 12,605 15.59
2024-12-05BUY21213.65014.480 14.397USD 3,052 15.66
2024-12-04BUY1,06014.49015.040 14.985USD 15,884 15.70
2024-11-29BUY1,06015.62015.690 15.683USD 16,624 15.75
2024-11-27BUY84815.21015.460 15.435USD 13,089 15.79
2024-11-26BUY21214.73014.772 14.768USD 3,131 15.84
2024-11-25BUY15,27314.79015.240 15.195USD 232,073 15.89
2024-11-21BUY82513.80014.390 14.331USD 11,823 16.08
2024-11-20BUY49513.12014.270 14.155USD 7,007 16.25
2024-11-18BUY1,98014.17015.200 15.097USD 29,892 16.51
2024-11-12BUY1,32016.65017.240 17.181USD 22,679 16.50
2024-11-08BUY82516.73016.995 16.969USD 13,999 16.49
2024-11-07BUY2,46016.00017.150 17.035USD 41,906 16.52
2024-11-06BUY32816.06016.230 16.213USD 5,318 16.56
2024-10-31BUY16414.22014.520 14.490USD 2,376 17.39
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NTLA

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-192,488,21625,9124,783,02652.0%
2025-09-183,275,17025,8088,092,76240.5%
2025-09-171,795,7605,8053,049,64858.9%
2025-09-16882,7801,1103,448,05925.6%
2025-09-15742,270871,788,36241.5%
2025-09-12722,3354001,382,22152.3%
2025-09-11875,8647,0541,871,68146.8%
2025-09-101,504,2395,7622,264,60066.4%
2025-09-091,403,87413,3412,383,47558.9%
2025-09-08918,1171381,520,95960.4%
2025-09-051,009,1372,1442,403,55642.0%
2025-09-04673,3557,2371,306,22151.5%
2025-09-031,086,3501,5832,619,35341.5%
2025-09-02670,3971,1671,423,04747.1%
2025-08-29537,4682,1001,149,46646.8%
2025-08-28861,12701,850,84046.5%
2025-08-27562,88531,151,55148.9%
2025-08-26587,4712181,339,28243.9%
2025-08-25944,6762,5342,848,39633.2%
2025-08-22471,9941,0101,271,51237.1%
2025-08-21664,42001,098,36860.5%
2025-08-20717,6611751,330,49753.9%
2025-08-191,307,3613,2091,995,17365.5%
2025-08-18749,6934,8521,667,25045.0%
2025-08-15929,7746292,294,40440.5%
2025-08-141,573,7209482,631,09059.8%
2025-08-131,587,3051,2572,999,67352.9%
2025-08-12943,0332,9121,526,98161.8%
2025-08-11673,8925961,352,23349.8%
2025-08-081,135,0265,9191,684,23567.4%
2025-08-07930,5373051,823,81751.0%
2025-08-06841,9404551,751,62648.1%
2025-08-05766,4981531,479,64951.8%
2025-08-04806,2139811,511,50753.3%
2025-08-011,211,5522,1212,016,62260.1%
2025-07-311,494,6036,2362,951,39850.6%
2025-07-30876,6011,3001,994,39444.0%
2025-07-29903,3802,8932,182,94441.4%
2025-07-28602,1541,7131,783,81433.8%
2025-07-25830,629114,1572,043,99840.6%
2025-07-241,624,048106,0133,581,47745.3%
2025-07-231,590,06513,5703,054,68352.1%
2025-07-22899,4603,2991,834,33049.0%
2025-07-211,344,5376,3712,694,80349.9%
2025-07-18725,1296321,386,25452.3%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy